MyOme alternatives and competitors
The closest alternatives to MyOme are Allelica, Ambry Genetics, Myriad Genetics and Genomics.
MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores.
10 alternatives to MyOme
What each product does, with its price as the vendor publishes it.
-
A
Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways.
Price: No published price
-
A
Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI.
-
M
Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories.
Price: Most eligible patients pay $0; financial assistance tiers of $0, $100 or $249
-
G
Genomics trades as Genomics and is registered in England as Genomics Ltd, formerly Genomics plc. Its US arm, Genomics Inc., is wholly owned by Genomics Ltd.
Price: No published price
-
H
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.
Price: No published price
-
G
Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases.
Price: No published price
-
I
Invitae is a genetic testing brand owned by Labcorp, which acquired the business in 2024 after Invitae's bankruptcy. It keeps its own site and test menu and now presents itself as Invitae and Labcorp together, with some billing handled by Labcorp Genetics.
Price: No published price
-
B
Precision oncology company in Waltham, Massachusetts, combining sequencing in its own CAP accredited, CLIA certified laboratory with models of tumor and immune biology.
Price: No published price
-
G
Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.
Price: $949 per test (list price)
-
C
Caris Life Sciences (NASDAQ: CAI) is a precision oncology company in Irving, Texas. It profiles tumors in its own laboratories by whole exome and whole transcriptome sequencing and layers AI signatures on the results.
Price: No published price
MyOme alternatives, answered
What are the best alternatives to MyOme?
The closest alternatives to MyOme are Allelica, Ambry Genetics, Myriad Genetics, Genomics and Helix. Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways. Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI. Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories.
Who are MyOme's competitors?
MyOme's competitors in the Diagnostics & Genomics category include Allelica, Ambry Genetics, Myriad Genetics, Genomics, Helix and GeneDx.